ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AKBA Akebia Therapeutics Inc

1.2289
-0.0611 (-4.74%)
Last Updated: 20:09:06
Delayed by 15 minutes
Share Name Share Symbol Market Type
Akebia Therapeutics Inc NASDAQ:AKBA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0611 -4.74% 1.2289 1.22 1.23 1.268 1.20 1.26 1,660,464 20:09:06

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/06/2023 9:05pm

PR Newswire (US)


Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Akebia Therapeutics Charts.

CAMBRIDGE, Mass., June 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 29,000 shares of Akebia's common stock on May 31, 2023, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

The options have an exercise price of $1.04 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee's continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia's inducement award program and a stock option agreement covering the grant.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301840387.html

SOURCE Akebia Therapeutics

Copyright 2023 PR Newswire

1 Year Akebia Therapeutics Chart

1 Year Akebia Therapeutics Chart

1 Month Akebia Therapeutics Chart

1 Month Akebia Therapeutics Chart

Your Recent History

Delayed Upgrade Clock